Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27

PRECIGEN, INC.

2025-Q1 EPS reported -$0.18 revenue$1,341,000

Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.
Cash and investments $81.0M as of March 31, 2025; Q1 cash burn $16.9M; runway into 2026.
BLA for PRGN-2012 (RRP) under FDA priority review; PDUFA target action date August 27, 2025.
Pivotal study: 51% complete response, 86% reduction in surgeries; median follow-up 30 months.
Selected EVERSANA for commercialization support; advancing launch readiness for potential 2025 launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.